165 related articles for article (PubMed ID: 25450286)
1. Prostate cancer antigen 3 as a biomarker in the urine for prostate cancer diagnosis: a meta-analysis.
Xue WJ; Ying XL; Jiang JH; Xu YH
J Cancer Res Ther; 2014 Nov; 10 Suppl():C218-21. PubMed ID: 25450286
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis.
Cui Y; Cao W; Li Q; Shen H; Liu C; Deng J; Xu J; Shao Q
Sci Rep; 2016 May; 6():25776. PubMed ID: 27161545
[TBL] [Abstract][Full Text] [Related]
3. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
Cui C; Sun X; Zhang J; Han D; Gu J
J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
5. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
[TBL] [Abstract][Full Text] [Related]
6. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
[TBL] [Abstract][Full Text] [Related]
7. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.
Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G
J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of urine prostate cancer antigen 3 test using a cutoff value of 35 μg/L in patients with prostate cancer.
Hu B; Yang H; Yang H
Tumour Biol; 2014 Sep; 35(9):8573-80. PubMed ID: 24863945
[TBL] [Abstract][Full Text] [Related]
9. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ
J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
[TBL] [Abstract][Full Text] [Related]
10. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
[TBL] [Abstract][Full Text] [Related]
11. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
[TBL] [Abstract][Full Text] [Related]
12. PSAD Test in the Diagnosis of Prostate Cancer: a Meta-Analysis.
Feng ZJ; Xue C; Wen JM; Li Y; Wang M; Zhang N
Clin Lab; 2017 Jan; 63(1):147-155. PubMed ID: 28164507
[TBL] [Abstract][Full Text] [Related]
13. Progensa™ PCA3 test for prostate cancer.
Durand X; Moutereau S; Xylinas E; de la Taille A
Expert Rev Mol Diagn; 2011 Mar; 11(2):137-44. PubMed ID: 21405964
[TBL] [Abstract][Full Text] [Related]
14. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?
Ploussard G; Haese A; Van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Bastien L; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; Van Gils MP; Schalken JA; de La Taille A
BJU Int; 2010 Oct; 106(8):1143-7. PubMed ID: 20230386
[TBL] [Abstract][Full Text] [Related]
15. Combination of real-time elastography and urine prostate cancer gene 3 (PCA3) detects more than 97% of significant prostate cancers.
Nygård Y; Haukaas SA; Waage JE; Halvorsen OJ; Gravdal K; Frugård J; Akslen LA; Beisland C
Scand J Urol; 2013 Jun; 47(3):211-6. PubMed ID: 23035756
[TBL] [Abstract][Full Text] [Related]
16. [Value of urinary PCA3 test for prostate cancer diagnosis].
Vlaeminck-Guillem V; Ruffion A; Andre J
Prog Urol; 2008 May; 18(5):259-65. PubMed ID: 18538269
[TBL] [Abstract][Full Text] [Related]
17. [Prostate health index in predicting the results of prostate biopsy for prostate cancer: a meta-analysis].
Liu Y; Xu Y; Zhang ZH; Yang K
Zhonghua Nan Ke Xue; 2014 Aug; 20(8):723-9. PubMed ID: 25195370
[TBL] [Abstract][Full Text] [Related]
18. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
[TBL] [Abstract][Full Text] [Related]
19. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer.
Rigau M; Ortega I; Mir MC; Ballesteros C; Garcia M; Llauradó M; Colás E; Pedrola N; Montes M; Sequeiros T; Ertekin T; Majem B; Planas J; Ruiz A; Abal M; Sánchez A; Morote J; Reventós J; Doll A
Prostate; 2011 Dec; 71(16):1736-45. PubMed ID: 21520154
[TBL] [Abstract][Full Text] [Related]
20. Comparison of diagnostic efficacy by two urine PCA3 scores in prostate cancer patients undergoing repeat biopsies.
Jiang Z; Zhao Y; Tian Y
Minerva Urol Nefrol; 2019 Aug; 71(4):373-380. PubMed ID: 30203935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
